Project Name: Pharmacist Led Lipid Service at West Middlesex University Hospital

Project Summary:

The CWP is structured such that a multi-disciplinary health professional team will provide tailored care for patients, aligned with the Primary Care Network (PCN) Contract Direct Enhanced Service (DES) and the locally defined cardiovascular plans.

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimization of patients with atherosclerotic cardiovascular disease (ASCVD) who are at high risk of cardiovascular events and who are not achieving lipid levels as specified in national and/or local guidance, in response to the needs of the CW Partner. Novartis will contract with Chelsea and Westminster Hospital NHS Foundation Trust as they are the legal entity acting on behalf of the following locations.

  • Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH
  • West Middlesex University Hospital, Twickenham Road, Isleworth, TW7 6AF

This CWP aims to support the cardiology department at West Middlesex University Hospital with a 0.3 FTE Band 8b Specialist Pharmacist and 0.1 FTE Consultant Clinical Pharmacologist / Acute Physician.  The aim will be to optimise lipid therapy for people with ASCVD in West Middlesex University Hospital and from referrals received from PCNs in the Hounslow area.

The CWP will be led by a Specialist Pharmacist and Consultant Clinical Pharmacologist / Acute Physician alongside a multi-disciplinary team; including the borough CVD champion, Specialist Nurses, Trust HR Associate, Administrator, General Practitioners, and PCN Pharmacists aiming to achieve:   

  1. Identification of sub-optimally treated ASCVD patients who are at high risk of cardiovascular events and who are not achieving lipid levels as specified in national and/or local guidelines.
  2. Identification of ASCVD patients who are at higher risk of cardiovascular events and who have previously not tolerated or refused alternative lipid modification therapies.  
  3. Review of treatment options and decision on next steps in collaboration with ASCVD patients
  4. Counsel and optimize ASCVD patients where appropriate.  
  5. Early identification of at-risk patients who have not had intervention in their health and wellbeing. 
  6. Identification of ASCVD patients, following risk assessment review, of ASCVD patients who are sub-optimally treated.  
  7. On-going ASCVD patients support and annual review to ensure CVD outcomes improve equitably. 
  8. Education of clinical team in primary care on managing lipids including newer therapies to improve appropriate referral and shared care management.

Planned Milestones:

MilestoneDescription
1

CW Partner: 
Kick off meeting.

Collection of baseline data, in line with the above Project Outcome Measures & Data Collection table

Confirmation of clinical and operational pathway, policy and protocol creation, and readiness to begin the clinical activity (CW Partner 
shall ensure that the clinical staff covered by the Novartis Financial Contribution are in place, trained and ready to begin clinical activity). 

2CW Partner: 
Collection & submission of 3 months clinical activity data.
3CW Partner: 
Collection & submission of 6 months clinical activity data.
4

CW Partner: Collection & submission of 9 months clinical activity data.

5CW Partner: Collection & submission of 12 months clinical activity data.
6CW Partner: 
Development of business case to continue the service offered by this project.
Analysis of CWP data, submission of Final Project Report, Submission of Outcomes Summary

 

Expected Benefits:

For the Patient:

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.   
  • Enhanced experience around ASCVD with ongoing management of the condition.   
  • Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events.  
  • Easier access to lipid management care closer to home in the Primary Care setting
  • The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up. Thus, leveling health inequalities within the PCN.

For the CW Partner:

  • Increased proportion of ASCVD patients reviewed by primary care.   
  • Increased proportion of ASCVD patients receiving expert and timely review closer to home  
  • Reduction in ASCVD referral rates to secondary care  
  • Increased proportion of patients receiving guideline-directed pharmacotherapy  
  • Insight into benefits of primary care pharmacist led lipid management clinics in primary care.   
  • Support aligned to NHS Long Term Plan, CVDPREVENT, and Network Contract DES 

For Novartis: 

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine.  
  • Enhanced reputation and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities.    
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation  

Start Date & Duration: November 2023 for 18 months

GB2311201284